Overview

Japanese Phase I Study of AZD2014 in Advanced Solid Malignancies

Status:
Active, not recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to investigate the safety and tolerability of continuous and/or intermittent dosing of AZD2014 when given orally to patients with advanced solid malignancies.
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca